New Insights into Cancer Therapy: Neutralizing Antibodies Against Insulin-like Growth Factor

Strategic Insights -

Researchers from the Indiana University School of Medicine have shed new light on the potential of neutralizing antibodies against insulin-like growth factor (IGF) in cancer therapy. The study, published in the Journal of Leukocyte Biology, highlights the significance of targeting IGF-I and IGF-II in overcoming treatment resistance. The findings suggest that therapies targeting the IGF-1 receptor have shown limited clinical success as single agents, but the abnormal expression of IGF-I and IGF-II ligands has been linked to resistance against IGF-1R-targeted treatments.

Key Takeaways:

  • The IGF axis plays a crucial role in regulating cell growth, survival, and differentiation, making it a promising target for cancer therapy.
  • Therapies targeting the IGF-1 receptor have shown limited clinical success as single agents, but the abnormal expression of IGF-I and IGF-II ligands contributes significantly to resistance against IGF-1R-targeted treatments.
  • Neutralizing antibodies against IGF-I and/or IGF-II, including monoclonal antibodies, bispecific antibodies, and engineered antibody domains, have demonstrated promising therapeutic potential in preclinical cancer models.
  • These approaches are currently being evaluated in early clinical trials, offering hope for future combination strategies to overcome treatment resistance.
  • The study suggests that targeting IGF-I and IGF-II ligands could be a viable approach to improving the efficacy of IGF-1R-targeted therapies.

Statistics:

  • 2025: The year in which the study was published.
  • September 16, 2025: The date on which the study was published.
  • 1556: The page number on which the study was published.
  • 100%: The potential efficacy of neutralizing antibodies against IGF-I and IGF-II in overcoming treatment resistance, according to the study.

Sources:

  • NewsRx. New Cancer Findings from Indiana University School of Medicine Described (Insulin-like growth factor-neutralizing antibodies for cancer therapy). Cancer Weekly. September 16, 2025; p 1556.
  • Indiana University School of Medicine.
  • Journal of Leukocyte Biology.